New Delhi: A 30-year-old man was on Friday given the first dose of undertrial coronavirus vaccine Covaxin at Delhi’s All India Institute Of Medical Sciences. A total of 12 volunteers were called for a number of pre-tests that include blood and nasopharyngeal testing for COVID¬19.
After results, 10 healthy individuals were selected for the vaccine to be given in phases.
After the first dose, a report on their health condition will be submitted to the ethics committee, which will reviewing the entire process. 100 healthy people will be vaccinated at AIIMS during these trial.
Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), had recently got the approval for human clinical trials from the Drugs Controller General of India (DCGI).
AIIMS-Delhi is among the 12 institutes selected by the Indian Council for
Medical Research (ICMR) for conducting the first two phases of the randomised, double-blind, placebo-controlled clinical trials of Covaxin.
